Central Memory CD4 Cells Are an Early Indicator of Immune Reconstitution in HIV/AIDS Patients with Anti-Retroviral Treatment

REFERENCES

• Aiuti, F., Mezzaroma, I. (2006). Failure to reconstitute CD4+ T-cells despite suppression of HIV replication under HAART. AIDS Rev. 8:88–97.
   PubMed Web of Science ®Google Scholar
• Alexander, T. H., Ortiz, G. M., Wellons, M. F., Allen, A., Grace, E. J. 2nd, Schweighardt, B., Brancato, J., Sandberg, J. K., Furlan, S. N., Miralles, G. D., Nixon, D. F., Bartlett, J. A. (2003). Changes in CD4+ T-cell differentiation phenotype during structured treatment interruption in patients with chronic HIV-1 infection. J. Acquir. Immune Defic. Syndr. Dec 15;34(5):475–481.
   Google Scholar
• Bates, J. T., Bucy, R. P. (2005). Enhanced responsiveness to antigen contributes more to immunological memory in CD4+ T cells than increases in the number of cells. Immunology Nov;116(3):318–327.
   Google Scholar
• Benito, J. M., López, M., Lozano, S., Ballesteros, C., Martinez, P., González-Lahoz, J., Soriano, V. (2005). Differential upregulation of CD38 on different T-cell subsets may influence the ability to reconstitute CD4+ T cells under successful highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 38:373–381.
   PubMed Web of Science ®Google Scholar
• Benito, J. M., López, M., Lozano, S., Martinez, P., González-Lahoz, J., Soriano, V. (2004). CD38 expression on CD8+ T lymphocytes as a marker of residual virus replication in chronically HIV infected patients receiving antiretroviral therapy. AIDS Res Hum Retroviruses 20:227–233.
   Google Scholar
• Bostik, P., Noble, E. S., Mayne, A. E., Gargano, L., Villinger, F., Ansari, A. A. (2006). Central memory CD4 T cells are the predominant cell subset resistant to anergy in SIV disease resistant sooty mangabeys. AIDS 2006; 20:181–188.
   Google Scholar
• Bouscarat, F., Levacher, M., Landman, R., Muffat-Joly, M., Girard, P. M., Saimot, A. G., Brun-Vézinet, F., Sinet, M. (1998). Changes in blood CD8+ T lymphocyte activation status and plasma HIV-RNA levels during antiretroviral therapy. AIDS 12:1267–1273.
   PubMedGoogle Scholar
• Bucy, R. P. (2004). Viral and cellular dynamics in HIV disease. Curr HIV/AIDS Rep. Apr;1(1):40–46. Review.
   Google Scholar
• Cavert, W., Notermans, D. W., Staskus, K., Wietgrefe, S. W., Zupancic, M., Gebhard, K., Henry, K., Zhang, Z. Q., Mills, R., McDade, H., Schuwirth, C. M., Goudsmit, J., Danner, S. A., Haase, A. T. (1997). Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 276: 960–964.
   PubMed Web of Science ®Google Scholar
• Clumeck, N., Pozniak, A., Raffi, F., the EACS Executive Committee (2008). European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. 2008 British HIV Association. HIV Med. 9: 65–71.
   PubMed Web of Science ®Google Scholar
• Elrefaei, M., McElroy, M. D., Preas, C. P., Hoh, R., Deeks, S., Martin, J., Cao, H. (2004). Central memory CD4+ T cell responses in chronic HIV infection are not restored by antiretroviral therapy. J. Immunol. Aug 1;173(3):2184–2189.
   PubMed Web of Science ®Google Scholar
• Fritsch, R. D., Shen, X., Sims, G. P., Hathcock, K S., Hodes, R. J., Lipsky, P. E. (2005). Stepwise differentiation of CD4 memory T cells defined by expression of CCR7 and CD27. J. Immunol. 175:6489–6497.
   PubMed Web of Science ®Google Scholar
• Ganesan, A., Chattopadhyay, P. K., Brodie, T. M., Qin, J., Gu, W., Mascola, J. R., Michael, N. L., Follmann, D. A., Roederer, M. (2010). Infectious Disease Clinical Research Program HIV Working Group. Immunologic and virologic events in early HIV infection predict subsequent rate of progression. J. Infect. Dis. Jan 15;201(2):272–284.
   Google Scholar
• Giorgi, J. V., Detels, R. (1989). T-cell subset alterations in HIV-infected homosexual men: NIAID Multicenter AIDS cohort study. Clin. Immunol. Immunopathol. 52:10–18.
   PubMedGoogle Scholar
• Giorgi, J. V., Liu, Z., Hultin, L. E., Cumberland, W. G., Hennessey, K., Detels, R. (1993). Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study. J. Acquir. Immune Defic. Syndr. 6:904–912.
   PubMedGoogle Scholar
• Goicoechea, M., Smith, D. M., Liu, L., May, S., Tenorio, A. R., Ignacio, C. C., Landay, A., Haubrich R. (2006). Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. J. Infect. Dis. 194:29–37.
   PubMed Web of Science ®Google Scholar
• Heeregrave, E. J., Geels, M. J., Brenchley, J. M., Baan, E., Ambrozak, D. R., van der Sluis, R. M., Bennemeer, R., Douek, D. C., Goudsmit, J., Pollakis, G., Koup, R. A., Paxton, W. A. (2009). Lack of in vivo compartmentalization among HIV-1 infected naïve and memory CD4+ T cell subsets. Virology 393(1):24–32.
   Google Scholar
• Hirsch, H. H., Kaufmann, G., Sendi, P., Battegay, M. (2004). Immune reconstitution in HIV-infected patients. Clin. Infect. Dis. 38:1159–1166.
   PubMed Web of Science ®Google Scholar
• Hunt, P. W., Deeks, S. G., Rodriguez, B., Valdez, H., Shade, S. B., Abrams, D. I., Kitahata, M. M., Krone, M., Neilands, T. B., Brand, R. J., Lederman, M. M., Martin, J. N. (2003). Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS 17:1907–1915.
   PubMed Web of Science ®Google Scholar
• Jansen, C. A., van Baarle, D., Miedema, F. (2006). HIV-specific CD4+ T cells and viremia: who’s in control? Trends Immunol. 27(3):119–124.
   Google Scholar
• Kolber, M. A. (2008) CD38+CD8+ T-cells negatively correlate with CD4 central memorycells in virally suppressed HIV-1-infected individuals. AIDS 22(15):1937–1941.
   Google Scholar
• Kaufmann, G. R., Perrin, L., Pantaleo, G., Opravil, M., Furrer, H., Telenti, A., Hirschel, B., Ledergerber, B., Vernazza, P., Bernasconi, E., Rickenbach, M., Egger, M., Battegay, M. (2003). Swiss HIV Cohort Study Group. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch. Intern. Med. 163: 2187–2195.
   PubMed Web of Science ®Google Scholar
• Kaufmann, G. R., Zaunders, J., Cooper, D. A. (1999). Immune reconstitution in HIV-1 infected subjects treated with potent antiretroviral therapy. Sex Transm Infect. 75(4): 218–224.
   Google Scholar
• Lambotte, O., Demoustier, A., de Goër, M. G., Wallon, C., Gasnault, J., Goujard, C., Delfraissy, J. F., Taoufik, Y. (2002). Persistence of replication-competent HIV in both memory and naive CD4 T cell subsets in patients on prolonged and effective HAART. AIDS 16(16):2151–2157.
   Google Scholar
• Landay, A., da Silva, B. A., King, M. S., Albrecht, M., Benson, C., Eron, J., Glesby, M., Gulick, R., Hicks, C., Kessler, H., Murphy, R., Thompson, M., White, A. C. Jr., Wolfe, P., McMillan, F. I., Hanna, G. J. (2007). Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment. Clin. Infect. Dis. 44:749–754.
   PubMed Web of Science ®Google Scholar
• Lederman, M. M., Valdez, H. (2011). Immune restoration with antiretroviral therapies: implications for clinical management. JAMA 305(7):645–732.
   Google Scholar
• Letvin, N. L., Mascola, J. R., Sun, Y., Gorgone, D. A., Buzby, A. P., Xu, L., Yang, Z. Y., Chakrabarti, B., Rao, S. S., Schmitz, J. E., Montefiori, D. C., Barker, B. R., Bookstein, F. L., Nabel, G. J. (2006). Preserved CD4R central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 312:1530– 1533.
   PubMed Web of Science ®Google Scholar
• Muñoz-Calleja, C., Costantini, A., Silvestri, G., Butini, L., Regnery, C. M., Mancini, S., Montroni, M. (2001). Highly active antiretroviral therapy induces specific changes in effector and central memory T cell sub-populations. AIDS 15:1887–1890.
   PubMedGoogle Scholar
• Okoye, A., Meier-Schellersheim, M., Brenchley, J. M., Hagen, S. I., Walker, J. M., Rohankhedkar, M., Lum, R., Edgar, J. B., Planer, S. L., Legasse, A., Sylwester, A. W., Piatak, M. Jr., Lifson, J. D., Maino, V. C., Sodora, D. L., Douek, D. C., Axthelm, M. K., Grossman, Z, Picker, L. J. (2007). Progressive CD4+ central memory T cell decline results in CD4R effector memory insufficiency and overt disease in chronic SIV infection. J. Exp. Med. 204:2171–2185.
   Google Scholar
• Orendi, J. M., Bloem, A. C., Borleffs, J. C., Wijnholds, F. J., de Vos, N. M., Nottet, H. S., Visser, M. R., Snippe, H., Verhoef, J., Boucher, C. A. (1998). Activation and cell cycle antigens in CD4+ and CD8+ T cells correlate with plasma HIV-1 RNA level in HIV-1 infection. J. Infect. Dis. 178:1279–1287.
   PubMedGoogle Scholar
• Pakker, N. G., Notermans, D. W., de Boer, R. J., Roos, M. T., de Wolf, F., Hill, A., Leonard, J. M., Danner, S. A., Miedema, F., Schellekens, P. T. (1998). Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation. Nat. Med. 4:208–214.
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents (2009). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 2009; 1–161. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
   Google Scholar
• Potter, S. J., Lacabaratz, C., Lambotte, O., Perez-Patrigeon, S., Vingert, B., Sinet, M., Colle, J. H., Urrutia, A., Scott-Algara, D., Boufassa, F., Delfraissy, J. F., Thèze, J., Venet, A., Chakrabarti, L. A. (2007). Preserved central memory and activated effector memory CD4R T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study. J. Virol. 81: 13904–13915.
   PubMed Web of Science ®Google Scholar
• Robbins, G. K., Spritzler, J. G., Chan, E. S., Asmuth, D. M., Gandhi, R. T., Rodriguez, B. A., Skowron, G., Skolnik, P. R., Shafer, R. W., Pollard, R. B.; AIDS Clinical Trials Group 384 Team (2009). Incomplete Reconstitution of T Cell Subsets on Combination Antiretroviral Therapy in the AIDS Clinical Trials Group Protocol 384. Clin. Infect. Dis. 48:350–361.
   PubMed Web of Science ®Google Scholar
• Sallusto, F., Geginat, J., Lanzavecchia, A. (2004). Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 22:745–763;
   PubMed Web of Science ®Google Scholar
• Sallusto, F., Lenig, D., Förster, R., Lipp, M., Lanzavecchia, A. (1999). Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401:708–771.
   PubMed Web of Science ®Google Scholar
• Sester, U., Sester, M., Köhler, H., Pees, H. W., Gärtner BC, Wain-Hobson S, Bocharov GMeyerhans A. Maintenance of HIV-specific central and effector memory CD4 and CD8 T cells requires antigen persistence. AIDS Res Hum Retroviruses. 2007 Apr;23(4):549–53.
   Google Scholar
• Seder, R. A., Ahmed, R. (2003). Similarities and differences in CD4+ and CD8+ effector and memory T cell generation. Nat. Rev. Immunol. 4:835–842.
   Google Scholar
• Williams, M. A., Bevan, M. J. (2007). Effector and memory CTL differentiation. Annu. Rev. Immunol. 25:171–192.
   PubMed Web of Science ®Google Scholar
• Wu, C. Y., Kirman, J. R., Rotte, M. J., (2002). Distinct lineages of T(H)1 cells have differential capacities for memory cell generation in vivo. Nat. Immunol. 3:852–858.
   PubMed Web of Science ®Google Scholar
• Zanetti, M., Franchini, G. T. (2006). T cell memory and protective immunity by vaccination: is more better? Trends Immunol. 27:511–517.
   PubMed Web of Science ®Google Scholar
• Zaph, C., Uzonna, J., Beverley, S. M., Scott, P. (2004). Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites. Nat. Med. 10:1104–1110.
   PubMed Web of Science ®Google Scholar
• Zhou, H. Y., Zheng, Y. H., Zhang, C. Y., Chen, J., He, Y., Ding, P. P., Li. H. (2007). Evaluation of human immunodeficiency virus type 1-infected Chinese patients treated with highly active antiretroviral therapy for two years. Viral Immunol. 20(1):180–187.
   Google Scholar